论文部分内容阅读
目的:初步探讨III期非小细胞肺癌(NSCLC)患者中p53mRNA表达与新辅助化疗敏感性及预后的关系。方法:选取30例行新辅助化疗的III期NSCLC患者,应用RTPCR法分别检测肿瘤与同肺叶正常组织p53mRNA的表达,随访患者生存情况。结果:①肿瘤组织中p53mRNA表达阳性17例(56.7%),正常组织中3例(10%),二者有统计学差异(P<0.05);②所有患者中位生存时间为18.9个月。肿瘤组织中p53mRNA阳性者中位生存时间13.1个月,阴性者32.0个月,二者有统计学差别(P<0.05)。结论:III期NSCLC患者正常组织中p53mRNA呈低表达,肿瘤组织中则呈高表达。p53mRNA表达可预测新辅助化疗的疗效。
Objective: To investigate the relationship between the p53 mRNA expression and the sensitivity and prognosis of neoadjuvant chemotherapy in stage III non-small cell lung cancer (NSCLC). Methods: Totally 30 patients with stage III NSCLC undergoing neoadjuvant chemotherapy were enrolled in this study. The expression of p53 mRNA in tumor and normal lung tissues was detected by RTPCR and the survival of patients were followed up. Results: ① The positive expression rate of p53 mRNA in tumor tissue was 17 cases (56.7%) and 3 cases (10%) in normal tissue. There was a significant difference between the two groups (P <0.05). ② The median survival time of all patients was 18.9 months. The median survival time was 13.1 months in patients with positive p53 mRNA and 32.0 months in patients with negative p53 mRNA (P <0.05). Conclusion: The expression of p53 mRNA in normal tissues of patients with stage III NSCLC is low and in tumor tissues is high. p53 mRNA expression predicts the efficacy of neoadjuvant chemotherapy.